Plain-English translation of NCT07400523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing ribociclib, a new medication, combined with therapy (a standard hormone treatment) in women with early-stage breast cancer. The study focuses on patients whose cancer didn't completely disappear after chemotherapy before surgery. Researchers want to see if adding ribociclib to the hormone therapy can help prevent the cancer from coming back and improve long-term survival.
Some breast cancers don't fully respond to chemotherapy before surgery, which means they carry a higher risk of returning. This medication works by blocking cancer cell growth in a different way than chemotherapy, so combining it with standard hormone therapy may offer better protection against recurrence.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either take the new medication plus hormone therapy, or hormone therapy alone. You'll take your assigned treatment for an extended period while visiting the research center regularly for check-ups, blood tests, and scans to monitor how you're responding. The study involves multiple visits over several years to track your health and see whether the medication helps prevent cancer recurrence.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China